AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
THOUSAND OAKS, Calif., May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
加利福尼亚州千橡市，2024年5月15日 /PRNewswire/ — 在TEZSPIRE公布新数据后，安进（纳斯达克股票代码：AMGN）将于太平洋时间2024年5月20日星期一下午1点为投资界举办网络直播电话会议 在2024年5月19日和20日的美国胸科学会（ATS）国际会议上，研究慢性阻塞性肺病（COPD）。该演讲还将概述安进创新炎症产品组合中的其他项目。安进研发执行副总裁兼首席科学官杰伊·布拉德纳以及安进团队的其他成员将参加。网络直播将同时通过互联网播出，并将向新闻媒体成员、投资者和公众开放。
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
该网络直播，以及管理层在某些投资者和医疗会议上发表的关于安进业务发展的其他精选演讲，可以在安进的网站上找到， www.amgen.com，在 “投资者” 下。安进的投资者关系活动日历上注明了有关演讲时间、网络直播可用性和网络直播链接的信息。网络直播将在活动结束后至少 90 天内存档并可供重播。
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
关于安进
安进发现、开发、制造和交付创新药物，以帮助数百万患者对抗世界上一些最棘手的疾病。40多年前，安进帮助建立了生物技术行业，并一直处于创新的前沿，利用技术和人类遗传数据来超越当今的已知水平。安进正在推进广泛而深入的产品线，该产品线建立在其现有药物组合的基础上，用于治疗癌症、心脏病、骨质疏松症、炎症性疾病和罕见疾病。
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average, and it is also part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
2024年，安进被Fast Company评为 “全球最具创新力的公司” 之一，被《福布斯》等评为 “美国最佳大型雇主” 之一 外部识别。安进是构成道琼斯工业平均指数的30家公司之一，它也是纳斯达克100指数的一部分，其中包括按市值在纳斯达克股票市场上市的最大、最具创新性的非金融公司。
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
联系人：安进、千橡市
Elissa Snook，609-251-1407（媒体）
贾斯汀·克莱斯，805-313-9775（投资者）
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-host-conference-call-following-ats-2024-302146981.html
SOURCE Amgen
来源 Amgen